MX2009002471A - Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora. - Google Patents
Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora.Info
- Publication number
- MX2009002471A MX2009002471A MX2009002471A MX2009002471A MX2009002471A MX 2009002471 A MX2009002471 A MX 2009002471A MX 2009002471 A MX2009002471 A MX 2009002471A MX 2009002471 A MX2009002471 A MX 2009002471A MX 2009002471 A MX2009002471 A MX 2009002471A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- tyrosine kinase
- receptor tyrosine
- drugs targeting
- ret receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona un método para la selección de un paciente, que es un candidato para el tratamiento con un fármaco e RET, mediante el cual se pronosticar una probabilidad creciente de respuesta a un fármaco de RET. La invención proporciona un método para determinar la secuencia de RET. El método proporciona los cebadores de ARMS optimizados para determinar la secuencia de RET. La invención también proporciona un kit de diagnóstico, que comprende un cebador de ARMS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84276606P | 2006-09-07 | 2006-09-07 | |
| PCT/GB2007/003335 WO2008029123A1 (en) | 2006-09-07 | 2007-09-06 | Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009002471A true MX2009002471A (es) | 2009-03-20 |
Family
ID=38829617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009002471A MX2009002471A (es) | 2006-09-07 | 2007-09-06 | Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110028498A1 (es) |
| EP (1) | EP2064340A1 (es) |
| JP (1) | JP2010502209A (es) |
| KR (1) | KR20090048644A (es) |
| CN (1) | CN101512017A (es) |
| AU (1) | AU2007293280A1 (es) |
| BR (1) | BRPI0716555A2 (es) |
| CA (1) | CA2662591A1 (es) |
| IL (1) | IL197157A0 (es) |
| MX (1) | MX2009002471A (es) |
| NO (1) | NO20090788L (es) |
| WO (1) | WO2008029123A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802384B2 (en) * | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| WO2012166899A2 (en) * | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| JP2014533508A (ja) * | 2011-11-17 | 2014-12-15 | リーアニクス・インコーポレイテッドＲｈｅｏｎｉｘ， Ｉｎｃ． | 選択的分子分析のためのシステムおよび方法 |
| US9580514B2 (en) * | 2012-05-14 | 2017-02-28 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| KR102204279B1 (ko) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지 |
| JP6130755B2 (ja) * | 2013-08-12 | 2017-05-17 | ルネサスエレクトロニクス株式会社 | 半導体装置およびその製造方法 |
| RS63559B1 (sr) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | Derivat hinolina velike čistoće i postupak za njegovu proizvodnju |
| PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| WO2017134115A1 (en) * | 2016-02-01 | 2017-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for determining responsiveness to vandetanib in a patient suffering from medullary thyroid carcinoma |
| CN110446790B (zh) * | 2016-11-30 | 2023-03-31 | 外来体诊断公司 | 使用外来体rna和无细胞dna检测血浆中的突变的方法和组合物 |
| CN109439752B (zh) * | 2018-11-16 | 2022-02-15 | 上海派森诺医学检验所有限公司 | 一种鉴别甲状腺髓样癌ret基因突变的特异性引物组合及其试剂盒及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| ITMI20021620A1 (it) * | 2002-07-23 | 2004-01-23 | Novuspharma Spa | Composto ad ativita' antitumorale |
-
2007
- 2007-09-06 MX MX2009002471A patent/MX2009002471A/es not_active Application Discontinuation
- 2007-09-06 EP EP07804140A patent/EP2064340A1/en not_active Withdrawn
- 2007-09-06 JP JP2009527195A patent/JP2010502209A/ja active Pending
- 2007-09-06 BR BRPI0716555-2A2A patent/BRPI0716555A2/pt not_active IP Right Cessation
- 2007-09-06 CA CA002662591A patent/CA2662591A1/en not_active Abandoned
- 2007-09-06 CN CNA2007800330353A patent/CN101512017A/zh active Pending
- 2007-09-06 US US12/438,306 patent/US20110028498A1/en not_active Abandoned
- 2007-09-06 AU AU2007293280A patent/AU2007293280A1/en not_active Abandoned
- 2007-09-06 WO PCT/GB2007/003335 patent/WO2008029123A1/en active Application Filing
- 2007-09-06 KR KR1020097006399A patent/KR20090048644A/ko not_active Application Discontinuation
-
2009
- 2009-02-19 IL IL197157A patent/IL197157A0/en unknown
- 2009-02-19 NO NO20090788A patent/NO20090788L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20090788L (no) | 2009-03-13 |
| BRPI0716555A2 (pt) | 2013-09-24 |
| CN101512017A (zh) | 2009-08-19 |
| WO2008029123A1 (en) | 2008-03-13 |
| KR20090048644A (ko) | 2009-05-14 |
| CA2662591A1 (en) | 2008-03-13 |
| AU2007293280A1 (en) | 2008-03-13 |
| EP2064340A1 (en) | 2009-06-03 |
| JP2010502209A (ja) | 2010-01-28 |
| IL197157A0 (en) | 2009-11-18 |
| US20110028498A1 (en) | 2011-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009002471A (es) | Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora. | |
| HK1136943A1 (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | |
| EA201100621A1 (ru) | Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством | |
| EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
| MX2009000385A (es) | Acil-anilidas sustituidas y metodos de uso de las mismas. | |
| EA201190053A1 (ru) | Агонисты рецептора gpr120 и их применение | |
| WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
| EA201170504A1 (ru) | Арильные агонисты рецептора gpr120 и их применение | |
| MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
| EA201100335A1 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
| MX2009001962A (es) | Acilanilidas substituidas y metodos de uso de las mismas. | |
| WO2010003313A8 (zh) | 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 | |
| WO2011154139A3 (en) | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment | |
| WO2010059969A8 (en) | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer | |
| WO2010028373A3 (en) | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients | |
| TW200833688A (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | |
| CO6382138A2 (es) | N-cadherina: blanco para diagnosis y terapia de cáncer | |
| WO2010116088A3 (fr) | Dérivés de quinazolinedione, leur préparation et leurs diverses applications thérapeutiques | |
| EA201071146A1 (ru) | Способы диагностирования, предупреждения и лечения болезней, связанных с костной массой | |
| MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
| ATE529750T1 (de) | Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target | |
| WO2009016231A3 (en) | Compositions and methods for detecting histamine related disorders | |
| WO2010001369A3 (es) | Métodos para el tratamiento y diagnóstico del cáncer | |
| WO2007085958A3 (en) | Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker | |
| NO20085290L (no) | Metode |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |